Comparative Cost-Effectiveness of Tofacitinib With Continuing Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs for Active Rheumatoid Arthritis in South Korea | Rheumatology and Therapy
Biomolecules | Free Full-Text | Biomarkers to Personalize the Treatment of Rheumatoid Arthritis: Focus on Autoantibodies and Pharmacogenetics
Patient disposition. DMARD, disease-modifying antirheumatic drug; mITT,... | Download Scientific Diagram
Conventional disease‐modifying antirheumatic drugs to treat rheumatoid arthritis - Rath - 2011 - Drug Development Research - Wiley Online Library
LIST OF DMARDS USED TO TREAT RHEUMATOID ARTHRITIS | Download Table
Disease-Modifying Antirheumatic Drug - an overview | ScienceDirect Topics
Schematic of the trial design. DMARD disease modifying antirheumatic... | Download Scientific Diagram
The Safety of Antirheumatic Drugs (11.02.2022)
Facilitators and Barriers to Adherence in the Initiation Phase of Disease-modifying Antirheumatic Drug (DMARD) Use in Patients with Arthritis Who Recently Started Their First DMARD Treatment | The Journal of Rheumatology
Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis | Rheumatology and Therapy
Conventional disease-modifying anti-rheumatic drugs combined with Chinese Herbal Medicines for rheumatoid arthritis: A systematic review and meta-analysis - ScienceDirect
Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in
Emerging Treatments for Rheumatoid Arthritis: Update | Consultant360
Medicina | Free Full-Text | Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents
Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan | springermedizin.de
Rheumatoid arthritis: Finding the right treatment can take years, Part 2 - Prime Therapeutics LLC
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update | Annals of the Rheumatic Diseases
Biologic and Targeted Synthetic DMARD Utilization in the United States: Adelphi Real World Disease Specific Programme for Rheumatoid Arthritis | Rheumatology and Therapy
Emerging Treatments for Rheumatoid Arthritis: Update | Consultant360
Real-world treatment patterns of rheumatoid arthritis in Brazil: analysis of DATASUS national administrative claims data for pharmacoepidemiology studies (2010–2020) | Scientific Reports
Disease-modifying antirheumatic drug-free sustained remission in rheumatoid arthritis: an increasingly achievable outcome with subsidence of disease symptoms | Annals of the Rheumatic Diseases
Traditional disease-modifying antirheumatic drugs (DMARDs) | Download Table
Frontiers | The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions
The Korean Journal of Internal Medicine
Treatment of Juvenile Idiopathic Arthritis | Pediatric Annals
JCM | Free Full-Text | Current Therapeutic Options in the Treatment of Rheumatoid Arthritis
Phytochemical add-on therapy to DMARDs therapy in rheumatoid arthritis: In vitro and in vivo bases, clinical evidence and future trends - ScienceDirect
Drugs used for arthritis. Conventional Disease Modifying Anti-Rheumatic... | Download Scientific Diagram
